A Phase 1 interventional study of SUN-101 via eFlow nebulizer and SUN-101 via eFlow nebulizer with activated charcoal in COPD, sponsored by Sunovion Respiratory Development Inc.. Completed at 2 sites in United Kingdom. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-10-25.
Sponsored by Sunovion Respiratory Development Inc. (part of Sumitomo Pharma Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 64th largest by enrollment, is one of 8 that started in 2015, is one of 7 in phase 1, and was the 50th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 857 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in Germany, United Kingdom
Ages 40–80
AstraZeneca · Sites in United States, Argentina, Australia and 34 more countries
Ages 40–80
By country, each count listing its studies:
Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 557 Pulmonary Disease, Chronic Obstructive studies recruiting now, 306 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 89 take healthy volunteers.
This study: 40 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
73 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 21 · Phase 3 33 · Phase 4 11
First in 2005; this study’s year is marked. 8 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 62 across 3,840 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 152 across the 73 interventional studies. Of the 67 that completed or were terminated, 49 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
67 of 73 have an industry lead sponsor. The 10 most frequent:
This study is registered under Sunovion Respiratory Development Inc., one of the names counted as Sumitomo Pharma Co., Ltd.. Under that name alone:
Sunovion Respiratory Development Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd.: none open now, none under way, none of them phase 3. Of 24 finished, 15 (63%) have results posted.
Among the 24 studies in Pulmonary Disease, Chronic Obstructive by Sumitomo Pharma Co., Ltd., this one is the 22nd largest by enrollment, is one of 3 that started in 2015, is the only one in phase 1, and was the 21st registered.
Sumitomo Pharma Co., Ltd.’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 2001.
1 of the studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07073950AstraZenecaA Study to Investigate the Effect of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Compared With Placebo MDI on Heart and Lung Function in Participants With Chronic Obstructive Pulmonary Disease (COPD) and Hyperinflation | 2027-05-31 |
Add it to your calendar (.ics) → With an account.
Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sumitomo Pharma Co., Ltd.’s 24 in Pulmonary Disease, Chronic Obstructive:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this research study is to determine the amount of medicine absorbed in the lungs following dosing via eFlow nebulizer and Seebri® Breezhaler® with and without activated charcoal in subjects with moderate to severe chronic obstructive pulmonary disease (COPD).
This is a randomized, open-label, single-dose per dosing period, five-way crossover study in subjects 40 to 70 years of age with a diagnosis of moderate to severe COPD per Global Initiative for Chronic Obstructive Lung Disease guidelines. After a subject provides consent for study participation, there will be a Screening Period lasting up to 3 weeks to determine study eligibility and to allow for appropriate washout of prohibited medications.
Eligible subjects will be randomized to one of 10 treatment Sequences. There will be a minimum of a 7-day washout period between each treatment visit. At each visit, subjects will receive one dose of study medication according to the sequence assigned.
Subjects with a ≥ 20% decrease in forced expiratory volume in one second (FEV1) based on review of the Visit predose value compared with the Screening value will be evaluated by the investigator for continuation in the study.
Subjects taking theophylline will not be able to participate in the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Severe comorbidities including unstable cardiac or pulmonary disease or any other medical conditions that would, in the opinion of the Investigator, preclude the subject from safely completing the required tests or the study, or is likely to result in disease progression that would require withdrawal of the subject, included but not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
50 mcg glycopyrrolate via Electronic Nebulizer
Drug: SUN-101 via eFlow nebulizer
50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
Drug: SUN-101 via eFlow nebulizer with activated charcoal
63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Drug: Seebri® Breezhaler®
: : 63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Drug: Seebri® Breezhaler® with activated charcoal
50 mcg glycopyrrolate via IV infusion
Drug: Glycopyrrolate Injection
50 mcg glycopyrrolate via Electronic Nebulizer
Also known as: Glycopyrrolate
Drug page: Glycopyrrolate
50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
Also known as: Glycopyrrolate
63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
Also known as: glycopyrronium, glycopyrronium bromide
63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
Also known as: glycopyrronium, glycopyrronium bromide
50 mcg glycopyrrolate via IV
Also known as: Glycopyrrolate
Cmax
maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Area Under the Curve From Time Zero to 24 Hours (AUC0_24)
Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr
Time frame: Up to Week 5
Area Under the Curve From Time Zero to Infinity (AUC0_infinity)
calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / \| λz \| Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate
calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate
calculated as Dose/(AUC0-inf\*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate
The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate
calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ -
Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: Up to Week 5
Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101
calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: up to week 5
Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101
calculated as Dose/(AUC0-∞\* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr
Time frame: up to week 5
Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101
The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: up to week 5
Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101
calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
Time frame: up to week 5
Dose Normalized Cmax for Seebri and SUN-101.
Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
Time frame: up to week 5
Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
Time frame: up to week 5
Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
Time frame: up to week 5
Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor\* (AUC0-∞ = AUC0-last+ Clast / \| λz \| ) Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
Time frame: up to week 5
The Number of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.
Time frame: Up to Week 5
The Percentage of Subjects With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation
An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.
Time frame: Up to Week 5
| Milestone | Treatment Group One | Treatment Group Two | Treatment Group Three | Treatment Group Four | Treatment Group Five | Treatment Group Six | Treatment Group Seven | Treatment Group Eight | Treatment Group Nine | Treatment Group Ten |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 3 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 3 |
| Completed | 3 | 2 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 3 |
| Not completed | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group One | Treatment Group Two | Treatment Group Three | Treatment Group Four | Treatment Group Five | Treatment Group Six | Treatment Group Seven | Treatment Group Eight | Treatment Group Nine | Treatment Group Ten |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 2 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 3 |
| Completed | 3 | 2 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Milestone | Treatment Group One | Treatment Group Two | Treatment Group Three | Treatment Group Four | Treatment Group Five | Treatment Group Six | Treatment Group Seven | Treatment Group Eight | Treatment Group Nine | Treatment Group Ten |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 2 | 4 | 3 | 3 | 3 | 2 | 3 | 3 | 2 |
| Completed | 3 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Treatment Group One | Treatment Group Two | Treatment Group Three | Treatment Group Four | Treatment Group Five | Treatment Group Six | Treatment Group Seven | Treatment Group Eight | Treatment Group Nine | Treatment Group Ten |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 2 |
| Completed | 3 | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Milestone | Treatment Group One | Treatment Group Two | Treatment Group Three | Treatment Group Four | Treatment Group Five | Treatment Group Six | Treatment Group Seven | Treatment Group Eight | Treatment Group Nine | Treatment Group Ten |
|---|---|---|---|---|---|---|---|---|---|---|
| Started | 3 | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 2 |
| Completed | 3 | 2 | 3 | 3 | 3 | 3 | 1 | 3 | 3 | 2 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
maximum observed concentration-Cmax is calculated from plasma concentrations analyzed from blood samples collected between 0 and 48 hr.
| Pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal | : Glycopyrrolate Injection |
|---|---|---|---|---|---|
| Cmax | 53.75 ± 51.746 | 49.27 ± 60.996 | 166.79 ± 76.348 | 148.03 ± 39.841 | 3787.47 ± 115.166 |
Area under the drug concentration-time curve from time zero to 24 hours postdose pk parameteres are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr
| hr*pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal | : Glycopyrrolate Injection |
|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to 24 Hours (AUC0_24) | 172.23 ± 100.974 | 159.12 ± 92.720 | 472.35 ± 90.233 | 428.52 ± 46.985 | 1961.79 ± 142.488 |
calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity: AUC0-∞ = AUC0-last+ Clast / \| λz \| Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| hr*pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal | : Glycopyrrolate Injection |
|---|---|---|---|---|---|
| Area Under the Curve From Time Zero to Infinity (AUC0_infinity) | 234.23 ± 77.206 | 167.84 ± 41.208 | 607.53 ± 79.340 | 570.90 ± 63.913 | 2550.85 ± 117.068 |
calculated as Dose/AUC0-inf after the IV dose administration. If AUC0-inf is missing, then CL was considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| Liters/hr | : Glycopyrrolate Injection |
|---|---|
| Clearance (CL) for IV Infusion of 50 mcg of Glycopyrrolate | 19.60 ± 117.068 |
calculated as Dose/(AUC0-inf\*λz). Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| Liters | : Glycopyrrolate Injection |
|---|---|
| Volume of Distribution During the Elimination Phase (Vz) for IV Infusion of 50 mcg of Glycopyrrolate | 113.06 ± 131.141 |
The time 0 is based on start of the infusion. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| hr | : Glycopyrrolate Injection |
|---|---|
| Time of Occurrence of Cmax (Tmax) for IV Infusion of 50 mcg of Glycopyrrolate | 0.100 (0.08 to 0.40) |
calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| hr | : Glycopyrrolate Injection |
|---|---|
| Terminal Half Life (t1/2) for IV Infusion of 50 mcg of Glycopyrrolate | 3.998 ± 111.8589 |
Area under the drug concentration-time curve from time zero to 48 hours postdose Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| hr*pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri Breezhaler and Sun-101 AUC0-48, CL/F, Vz/F, Tmax, t½, and Dose Normalized Cmax, AUC0-24, AUC0-48, AUC0-∞ - AUC0-∞ - | 182.59 ± 112.339 | 179.78 ± 108.906 | 524.18 ± 99.365 | 485.99 ± 56.588 |
calculated as Dose/AUC0-∞ after extravascular dose administration, where F = Bioavailability. If AUC0-∞ is missing, then CL/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| L/hr | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Apparent Clearance Calculated as Dose/AUC0-INF After Extravascular Dose Administration of Seebri Breezhaler and SUN-101 | 213.47 ± 77.206 | 297.91 ± 41.208 | 103.70 ± 79.340 | 110.35 ± 63.913 |
calculated as Dose/(AUC0-∞\* λz), where F = Bioavailability. If AUC0-∞ is missing, then Vz/F is considered as missing. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr
| liters | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Apparent Volume of Distribution (Vz/F) After Extravascular Dose Administration of Seebri Breezhaler and SUN-101 | 1263.63 ± 31.716 | 1668.59 ± 17.994 | 1305.30 ± 23.585 | 1708.81 ± 22.543 |
The time 0 is based on start of the inhalation. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| hr | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Time of Occurrence of Cmax (Tmax) for Seebri Breezhaler and SUN-101 | 0.317 (0.08 to 12.05) | 0.250 (0.07 to 12.3) | 0.250 (0.03 to 1.57) | 0.250 (0.05 to 0.40) |
calculated as ln(2) / λz . At least 3 data points at the terminal elimination phase were required to determine t½. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr.
| hr | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Terminal Half Life (t1/2) for for Seebri Breezhaler and SUN-101 | 6.554 ± 135.6286 | 5.191 ± 61.4971 | 10.378 ± 80.1891 | 14.866 ± 69.3836 |
Maximum observed concentration multiplied by the dose normalization factor. Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
| Pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Dose Normalized Cmax for Seebri and SUN-101. | 85.46 ± 51.746 | 78.33 ± 60.996 | 150.11 ± 76.348 | 133.22 ± 39.841 |
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 24 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
| hr*pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Dose Normalized Area Under the Curve Zero to 24 Hours (AUC0_24) for Seebri and SUN-101 | 273.85 ± 100.974 | 253.00 ± 92.720 | 425.12 ± 90.233 | 385.67 ± 46.985 |
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from time zero to 48 hours postdose multiplied by the dose normalization factor. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50 mcg, the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
| hr*pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Dose Normalized Area Under the Curve Zero to 48 Hours (AUC0_48) for Seebri and SUN-101 | 290.32 ± 112.339 | 285.85 ± 108.906 | 471.76 ± 99.365 | 437.39 ± 56.588 |
Pk parameters are calculated from plasma concentration analyzed from blood samples collected between 0 and 48 hr. Area under the drug concentration-time curve from zero to infinity, calculated by summing AUC0-last and the AUC extrapolated from tlast to infinity multiplied by the dose normalization factor: dose normalization factor\* (AUC0-∞ = AUC0-last+ Clast / \| λz \| ) Clast / \| λz \| is the extrapolated area under the curve from tlast to infinity. If this quantity is greater than 20% of AUC0-∞, then AUC0-∞ was considered to be missing. The dose normalization factor calculation has two components: dose equivalent glycopyrrolate amount and the delivery efficiency (% dose delivered). For Sun-101 50mcg , the dose normalization factor is 1.59, for Seebri Breezhaler it is 0.9.
| hr*pg/mL | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal |
|---|---|---|---|---|
| Dose Normalized Area Under the Curve Zero From Zero to Infinity (AUC0_inf) for Seebri and SUN-101 | 372.42 ± 77.206 | 266.86 ± 41.208 | 546.78 ± 79.340 | 513.81 ± 63.931 |
An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.
| participants | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal | : Glycopyrrolate Injection |
|---|---|---|---|---|---|
| Adverse Events | 6 | 9 | 7 | 11 | 7 |
| Serious Adverse Events | 0 | 0 | 0 | 0 | 0 |
| Adverse events leading to discontinuation | 1 | 1 | 0 | 1 | 0 |
An adverse event (AE) that occurred on or after the first dose of study medication, any AE with a missing start date and a stop date on or after the first dose of study medication, or any AE with both a missing start and stop date.
| percentage of participants | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal | : Glycopyrrolate Injection |
|---|---|---|---|---|---|
| Adverse Events | 20.7 | 31.0 | 25.0 | 40.7 | 25.9 |
| Serious Adverse Events | 0 | 0 | 0 | 0 | 0 |
| Adverse events leading to discontinuation | 3.4 | 3.4 | 0 | 3.7 | 0 |
Collected over up to week 5. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SUN-101 Via eFlow Nebulizer | — | 0/29 (0%) | 1/29 (3.4%) |
| SUN-101 Via eFlow Nebulizer With Activated Charcoal | — | 0/29 (0%) | 3/29 (10.3%) |
| Seebri® Breezhaler® | — | 0/28 (0%) | 3/28 (10.7%) |
| Seebri® Breezhaler® With Activated Charcoal | — | 0/27 (0%) | 5/27 (18.5%) |
| : Glycopyrrolate Injection | — | 0/27 (0%) | 4/27 (14.8%) |
| Event | SUN-101 Via eFlow Nebulizer | SUN-101 Via eFlow Nebulizer With Activated Charcoal | Seebri® Breezhaler® | Seebri® Breezhaler® With Activated Charcoal | : Glycopyrrolate Injection |
|---|---|---|---|---|---|
| headacheNervous system disorders | 1/29 | 3/29 | 1/28 | 4/27 | 4/27 |
| back painMusculoskeletal and connective tissue disorders | 0/29 | 0/29 | 2/28 | 1/27 | 0/27 |
| Age, Categorical(Participants) | Total |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 22 |
| >=65 years | 8 |
| Sex: Female, Male(Participants) | Total |
|---|---|
| Female | 6 |
| Male | 24 |
| Ethnicity (NIH/OMB)(Participants) | Total |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 30 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Total |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 2 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 28 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Total |
|---|---|
| United Kingdom | 30 |
The record gives a start of Oct 2015, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2018, 2 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Glycopyrrolate
Pulmonary Disease, Chronic Obstructive →
Sunovion Respiratory Development Inc. →